Therole of the FPR2/ALX receptor in atherosclerosis development and plaque stability

Cardiovascular Research

Volumn 105, Issue 1, 2015, Pages 65-74

  Petri, Marcelo H ^a   Laguna Fernández, Andrés ^a   Gonzalez Diez, Maria ^b   Paulsson Berne, Gabrielle ^a   Hansson, Göran K ^a   Bäck, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Formyl peptide receptors; Inflammation; Lipid mediators; Smooth muscle cells

Indexed keywords

COLLAGEN; COLLAGENASE; CREATININE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; MESSENGER RNA; UNCLASSIFIED DRUG; FORMYL PEPTIDE RECEPTOR 2, MOUSE; FPR2 PROTEIN, HUMAN; LIPOXIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; AGE; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CAROTID ATHEROSCLEROSIS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VERY ELDERLY; ANIMAL; ATHEROSCLEROTIC PLAQUE; BONE MARROW TRANSPLANTATION; CAROTID ARTERY DISEASES; CAROTID ARTERY OBSTRUCTION; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANIMALS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CAROTID ARTERY DISEASES; CAROTID STENOSIS; COLLAGEN; FEMALE; HUMANS; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LDL; RECEPTORS, LIPOXIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84924373644     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu224     Document Type: Article

References (43)

1. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013;38:1092-1104.
2. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010;10:36-46.
3. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009;61:119-161.
4. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 2006;107:2123-2130.
5. Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, YokomizoT, Brink C. The lipoxin receptorALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006;58:463-487.
6. Bäck M, Powell WS, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol 2014;171:3551-3574.
7. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196:1025-1037.
8. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA 2010;107:1660-1665.
9. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol 2012;32:1970-1978.
10. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
11. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloidAproteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997;96:2914-2919.
12. Tam SP, Ancsin JB, Tan R, Kisilevsky R. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE2/2 mice. J Lipid Res 2005;46:2091-2101.
13. Dong Z, An F, WuT, Zhang C, Zhang M, Zhang Y, An G, An F. PTX3, a keycomponent of innate immunity, is induced bySAAvia FPRL1-mediated signaling in HAECs. J Cell Biochem 2011;112:2097-2105.
14. Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang XB, Mandal K, Xu Q, Yan ZQ. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:1551-1557.
15. Doring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S, Gallo RL, Weber C, Soehnlein O. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res 2012;110:1052-1056.
16. Zhao L, MoosMP, Grabner R, Pedrono F, Fan J, Kaiser B, John N, Schmidt S, Spanbroek R, Lotzer K, Huang L, Cui J, Rader DJ, Evans JF, Habenicht AJ, Funk CD. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004;10:966-973.
17. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999;103:1597-1604.
18. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008;22:3595-3606.
19. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009;113:429-437.
20. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004;172:4987-4994.
21. Bäck M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006;38: 493-502.
22. Bäck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009;15:3116-3132.
23. Gabrielsen A, Qiu H, Bäck M, Hamberg M, Hemdahl AL, Agardh H, Folkersen L, Swedenborg J, Hedin U, Paulsson-Berne G, HaeggstromJZ, Hansson GK. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J Mol Med (Berl) 2010;88:795-806.
24. Agardh HE, Folkersen L, Ekstrand J, Marcus D, Swedenborg J, Hedin U, Gabrielsen A, Paulsson-Berne G. Expression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis. J Intern Med 2011;269:200-210.
25. Gisterå A, Robertson AK, Andersson J, Ketelhuth DF, Ovchinnikova O, Nilsson SK, Lundberg AM, Li MO, Flavell RA, Hansson GK. Transforming growth factor-beta signaling inTcells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med 2013;5:196ra100.
26. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Acquisto F, Buckingham JC, Perretti M, Flower RJ. Anti-inflammatory role of the murine formylpeptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010;184:2611-2619.
27. Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower RJ, Vergnolle N, Nourshargh S, Perretti M. A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 2013; 122:608-617.
28. Nagy E, Andersson DC, Caidahl K, Eriksson MJ, Eriksson P, Franco-Cereceda A, Hansson GK, Bäck M. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 2011;123:1316-1325.
29. Miksa M, Komura H, WuR, Shah KG, Wang P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J Immunol Methods 2009;342:71-77.
30. Wantha S, Alard JE, Megens RT, van der Does AM, Doring Y, Drechsler M, Pham CT, Wang MW, Wang JM, Gallo RL, von Hundelshausen P, Lindbom L, Hackeng T, Weber C, Soehnlein O. Neutrophil-derived cathelicidin promotes adhesion of classical monocytes. Circ Res 2013;112:792-801.
31. Vukcevic M, Zorzato F, Spagnoli G, Treves S. Frequent calcium oscillations lead to NFAT activation in human immature dendritic cells. J Biol Chem 2010;285:16003-16011.
32. Chen JH, Riazy M, Smith EM, Proud CG, Steinbrecher UP, Duronio V. Oxidized LDL-mediated macrophage survival involves elongation factor-2 kinase. Arterioscler Thromb Vasc Biol 2009;29:92-98.
33. Lee HY, Kim SD, Baek SH, Choi JH, Bae YS. Role of formyl peptide receptor 2 on the serum amyloid A-induced macrophage foam cell formation. Biochem Biophys Res Commun 2013;433:255-259.
34. Dalli J, Consalvo AP, Ray V, Di Filippo C, D'Amico M, Mehta N, Perretti M. Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J Immunol 2013;190: 6478-6487.
35. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, Godson C. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 2010;24:4240-4249.
36. Ait-Oufella H, Pouresmail V, Simon T, Blanc-Brude O, Kinugawa K, Merval R, Offenstadt G, Leseche G, CohenPL, Tedgui A, Mallat Z. Defectivemer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:1429-1431.
37. Cattaneo F, Parisi M, Ammendola R. Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists. Int J Mol Sci 2013;14:7193-7230.
38. Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, Flower RJ, Perretti M. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci USA 2013;110:18232-18237.
39. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000;164: 2660-2666.
40. Viiri LE, Full LE, Navin TJ, Begum S, Didangelos A, Astola N, Berge RK, Seppala I, Shalhoub J, Franklin IJ, Perretti M, Lehtimaki T, Davies AH, Wait R, Monaco C. Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J Mol Cell Cardiol 2013; 54:65-72.
41. Bäck M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010;52:410-428.
42. Chen K, Le Y, Liu Y, GongW, Ying G, Huang J, Yoshimura T, Tessarollo L, Wang JM. A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses. J Immunol 2010;184:3331-3335.
43. Chen K, Liu M, Liu Y, Yoshimura T, ShenW, Le Y, Durum S, GongW, Wang C, Gao JL, Murphy PM, Wang JM. Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Invest 2013;123: 1694-1704.